**5. Conclusions**

In summary, the results of the studies described herein, are the first to demonstrate the impact of HDAC6 activation in the diabetic retina and to sugges<sup>t</sup> the potential therapeutic efficacy of HDAC6 specific inhibitors for the prevention of redox imbalance and injury to the retinal microvasculature in the diabetic milieu.

**Supplementary Materials:** The following are available online at http://www.mdpi.com/2076-3921/9/7/599/s1, Table S1: Demographics and clinical history of human postmortem retinal donors. Table S2: Biochemical parameters measured in the experimental rat groups. Table S3: Primer sequences used in the study. Figure S1: MTT Assay.

**Author Contributions:** Conceptualization, M.B. and F.L.P.; methodology, H.A., M.C.T., R.N.J. and D.R.G.; formal analysis, H.A. and M.C.T.; data curation, H.A., M.C.T., R.N.J.; writing—original draft preparation, H.A., M.C.T. and M.B.; writing—review and editing, D.R.G., M.C.T. and M.B.; supervision, M.K. and M.B.; funding acquisition, P.M.M. and M.B. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by the National Eye Institute for the financial support to M.B. (EY022416, EY028714) and P.M.M. (EY022704).

**Acknowledgments:** The authors acknowledge the outstanding technical support of Jianghe Yuan and Shubhra Rajpurohit.

**Conflicts of Interest:** The authors declare no conflict of interest.
